BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1493 related articles for article (PubMed ID: 23761549)

  • 21. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
    Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
    J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
    Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
    Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
    Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
    Karan B; Pourbagher A; Torun N
    J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffusion-Weighted MRI for the Initial Viability Evaluation of Parasites in Hepatic Alveolar Echinococcosis: Comparison with Positron Emission Tomography.
    Zheng J; Wang J; Zhao J; Meng X
    Korean J Radiol; 2018; 19(1):40-46. PubMed ID: 29353998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.
    Wu X; Kellokumpu-Lehtinen PL; Pertovaara H; Korkola P; Soimakallio S; Eskola H; Dastidar P
    NMR Biomed; 2011 Dec; 24(10):1181-90. PubMed ID: 21387451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial Staging of Locally Advanced Rectal Cancer and Regional Lymph Nodes: Comparison of Diffusion-Weighted MRI With 18F-FDG-PET/CT.
    Cerny M; Dunet V; Prior JO; Hahnloser D; Wagner AD; Meuli RA; Schmidt S
    Clin Nucl Med; 2016 Apr; 41(4):289-95. PubMed ID: 26828149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer.
    Dalah E; Moraru I; Paulson E; Erickson B; Li XA
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):633-40. PubMed ID: 24755533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET/MRI for the evaluation of patients with lymphoma: initial observations.
    Heacock L; Weissbrot J; Raad R; Campbell N; Friedman KP; Ponzo F; Chandarana H
    AJR Am J Roentgenol; 2015 Apr; 204(4):842-8. PubMed ID: 25794075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
    Giraudo C; Karanikas G; Weber M; Raderer M; Jaeger U; Simonitsch-Klupp I; Mayerhoefer ME
    J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study.
    Littooij AS; Kwee TC; de Keizer B; Bruin MC; Coma A; Beek FJ; Fijnheer R; Nievelstein RA
    J Magn Reson Imaging; 2015 Dec; 42(6):1646-55. PubMed ID: 25952024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.